Abstract:For patients with RCC and VTT, the developed and internally validated post-operative nomogram can be used to select patients who may benefit from aggressive surveillance regimens or adjuvant therapy clinical trials.
“…In the tumor stage subgroups, Katkoori et al showed that right‐sided RCC was associated with a higher ratio of level III inferior vena cava (IVC) tumor thrombus (T3b) patients than with left‐sided RCC. Other reports have shown incidence rates of right‐sided IVC tumor thrombus of 53.5%, 64% and 81% . Conversely, fewer patients had stage T3b disease on the right side than on the left side in this study.…”
Section: Discussioncontrasting
confidence: 49%
“…Other reports have shown incidence rates of right-sided IVC tumor thrombus of 53.5%, 64% and 81%. [14][15][16] Conversely, fewer patients had stage T3b disease on the right side than on the left side in this study. A similar trend was observed for stage T4, lymph node and organ metastasis RCC patients.…”
Background
Various prognostic characteristics have been established in the renal cell carcinoma (RCC). However, the impact of tumor laterality is unknown. The objective of the current study was to explore the predictive and prognostic impact of tumor laterality of RCC after surgery.
Methods
This investigation was a population‐based retrospective cohort study of patients with RCC from the surveillance, epidemiology, and end results (SEER) database in the USA. All patients received surgical treatment between January 2010 and December 2014. Cancer‐specific survival (CSS) measured from the time of surgery.
Results
This study identified 41 138 surgically treated RCC patients: Of these patients, 50.6% had right‐sided RCC, 59.5% were younger than 65 years of age, 63.8% were male, and 81.0% were Caucasian. The stage distribution was 67.0% (I), 9.5% (II), 17.1% (III), and 6.4% (IV). Patients with right‐sided RCC were more likely to have favorable clinicopathological features compared with patients with left‐sided RCC. In adjusted analyses, patients with right‐sided RCC showed significantly better CSS than those with left‐sided RCC within different subgroups including tumor size ≥10 cm (P = .004), age <65 years (P = .002), male gender (P = .001), Caucasian race (P = .001), clear cell carcinoma type (P = .024), and radical nephrectomy (P = 0.008). Moreover, in the subgroup of tumor size ≥10 cm, right‐sided cancer was an independent predictor of CSS (P = .022).
Conclusion
Right‐sided RCC is associated with more early‐stage, low‐grade disease and shows better CSS than left‐sided RCC. Moreover, laterality remained as an independent prognostic factor for cancer‐specific survival in subgroup of tumor size ≥10 cm RCC.
“…In the tumor stage subgroups, Katkoori et al showed that right‐sided RCC was associated with a higher ratio of level III inferior vena cava (IVC) tumor thrombus (T3b) patients than with left‐sided RCC. Other reports have shown incidence rates of right‐sided IVC tumor thrombus of 53.5%, 64% and 81% . Conversely, fewer patients had stage T3b disease on the right side than on the left side in this study.…”
Section: Discussioncontrasting
confidence: 49%
“…Other reports have shown incidence rates of right-sided IVC tumor thrombus of 53.5%, 64% and 81%. [14][15][16] Conversely, fewer patients had stage T3b disease on the right side than on the left side in this study. A similar trend was observed for stage T4, lymph node and organ metastasis RCC patients.…”
Background
Various prognostic characteristics have been established in the renal cell carcinoma (RCC). However, the impact of tumor laterality is unknown. The objective of the current study was to explore the predictive and prognostic impact of tumor laterality of RCC after surgery.
Methods
This investigation was a population‐based retrospective cohort study of patients with RCC from the surveillance, epidemiology, and end results (SEER) database in the USA. All patients received surgical treatment between January 2010 and December 2014. Cancer‐specific survival (CSS) measured from the time of surgery.
Results
This study identified 41 138 surgically treated RCC patients: Of these patients, 50.6% had right‐sided RCC, 59.5% were younger than 65 years of age, 63.8% were male, and 81.0% were Caucasian. The stage distribution was 67.0% (I), 9.5% (II), 17.1% (III), and 6.4% (IV). Patients with right‐sided RCC were more likely to have favorable clinicopathological features compared with patients with left‐sided RCC. In adjusted analyses, patients with right‐sided RCC showed significantly better CSS than those with left‐sided RCC within different subgroups including tumor size ≥10 cm (P = .004), age <65 years (P = .002), male gender (P = .001), Caucasian race (P = .001), clear cell carcinoma type (P = .024), and radical nephrectomy (P = 0.008). Moreover, in the subgroup of tumor size ≥10 cm, right‐sided cancer was an independent predictor of CSS (P = .022).
Conclusion
Right‐sided RCC is associated with more early‐stage, low‐grade disease and shows better CSS than left‐sided RCC. Moreover, laterality remained as an independent prognostic factor for cancer‐specific survival in subgroup of tumor size ≥10 cm RCC.
“…Initially identi ed 267 articles through the search strategy, 19 studies remained after removing duplicates and excluding articles by viewing titles and abstracts. Based on corresponding inclusion and exclusion criteria, 8 articles comprising 5,025 patients were nally included in the present study [14,15,[18][19][20][21][22][23] ( Figure 1). All studies had a retrospective design, two of which were propensity score-matched analyses.…”
Section: Study Characteristicsmentioning
confidence: 99%
“…3 studies focused on metastatic RCC [19,21,22], 5 studies focused on non-metastatic RCC [14,15,18,20,23]. These studies were conducted in ve countries, including China, Korea, Turkey, Japan, and the United States.…”
Section: Study Characteristicsmentioning
confidence: 99%
“…Seven studies including 4,782 patients recorded about OS [14,15,[18][19][20][21][22]. Since moderate heterogeneity was found, the random-effects model was adopted (I 2 = 47.5%, P = 0.076).…”
Background Previous studies have evaluated the associations of aspartate transaminase to alanine transaminase (De Ritis) ratio with clinical outcome of renal cell carcinoma (RCC), but the findings are inconsistent. We therefore performed this meta-analysis to explore the prognostic value of the pre-treatment De Ritis ratio in patients with RCC.Methods PubMed, EMBASE, Science and Cochrane Library were searched systematically to identify all eligible studies as of February 2020. The hazard ratio (HR) with 95% confidence interval (CI) were extracted to evaluate their correlation.Results A total of 5,025 patients from 8 studies were included in the meta-analysis. Patients with an increased pre-treatment De Ritis ratio had worse overall survival (HR = 1.52, 95% CI 1.27 to 1.82, P < 0.001), cancer-specific survival (HR = 1.81, 95% CI 1.47 to 2.23, P < 0.001), progression-free survival (HR = 1.24, 95% CI 1.05 to 1.47, P = 0.011), and metastasis-free survival (HR = 1.61, 95% CI 1.25 to 2.07, P < 0.001). Subgroup analysis according to disease stage and cut-of value revealed that De Ritis ratio had a significant prognostic value for OS and PFS in all subgroups.Conclusion The available evidence suggests that an increased De Ritis ratio was significantly correlated with worse survival in patients with RCC. Pre-treatment De Ritis ratio may serve as a potential prognostic biomarker in patients with RCC, but further studies are warranted to support these results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.